Stromal cell biology:- A way to understand the evolution of cardiovascular diseases

Circulation Journal

Volumn 74, Issue 6, 2010, Pages 1042-1050

  Tsuruda, Toshihiro ^a   Imamura, Takuroh ^a   Hatakeyama, Kinta ^b   Asada, Yujiro ^b   Kitamura, Kazuo ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Adventitia; Angiogenesis; Fibroblast; Matrix metalloproteinase

Indexed keywords

ADRENOMEDULLIN; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ARGININE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE; NORADRENALIN; OXIDOREDUCTASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE INHIBITOR; SMALL INTERFERING RNA; STROMAL CELL DERIVED GROWTH FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; ATHEROSCLEROSIS; AUTOCRINE EFFECT; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL TYPE; CORONARY ARTERY OBSTRUCTION; CYTOLOGY; DISEASE COURSE; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME INHIBITION; FIBROBLAST; GENE TARGETING; HEART FUNCTION; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; MICROVASCULATURE; MYOFIBROBLAST; NONHUMAN; PARACRINE SIGNALING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; RNA INTERFERENCE; STROMA CELL; VASCULAR ENDOTHELIUM;

CARDIOVASCULAR DISEASES; CELL COMMUNICATION; DRUG DELIVERY SYSTEMS; HUMANS; STROMAL CELLS;

EID: 77953511026     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0024     Document Type: Article

References (121)

1. Espira L, Czubryt MP. Emerging concepts in cardiac matrix biology. Can J Physiol Pharmacol 2009; 87: 996-1008.
2. Weber KT, Brilla CG. Pathological hypertrophy and cardiac inter-stitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
3. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007; 446: 444-448.
4. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, et al. Transforming growth factor-ß function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106: 130-135.
5. Ferrari R, Ceconi C, Campo G, Cangiano E, Cavazza C, Secchiero P, et al. Mechanisms of remodelling: A question of life (stem cell production) and death (myocyte apoptosis). Circ J 2009; 73:1973-1982.
6. Menashi S, Campa JS, Greenhalgh RM, Powell JT. Collagen in abdominal aortic aneurysm: Typing, content, and degradation. J Vasc Surg 1987; 6: 578-582.
7. Zak R. Cell proliferation during cardiac growth. Am J Cardiol 1973; 31: 211-219.
8. Frank JS, Langer GA. The myocardial interstitium: Its structure and its role in ionic exchange. J Cell Biol 1974; 60: 586-601.
9. Spinale FG. Matrix metalloproteinases: Regulation and dysregula-tion in the failing heart. Circ Res 2002; 90: 520-530.
10. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: Interaction with hemodynamic and hormonal factors. Cardiovasc Res 1999; 41: 532-543.
11. Bou-Gharios G, Ponticos M, Rajkumar V, Abraham D. Extra-cellular matrix in vascular networks. Cell Prolif 2004; 37: 207-220.
12. Gutterman DD. Adventitia-dependent influences on vascular function. Am J Physiol 1999; 277: H1265-H1272.
13. Michel JB, Thaunat O, Houard X, Meilhac O, Caligiuri G, Nicoletti A. Topological determinants and consequences of adven-titial responses to arterial wall injury. Arterioscler Thromb Vasc Biol 2007; 27: 1259-1268.
14. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I: Paracrine cells important in health and disease. Am J Physiol 1999; 277: C1-C19.
15. Wilcox JN, Okamoto E, Nakahara K, Vinten-Johansen J. Peri-vascular responses after angioplasty which may contribute to postangioplasty restenosis: A role for circulating myofibroblast precursors? Ann N Y Acad Sci 2001; 947: 68-90.
16. Willems IE, Havenith MG, De Mey JG, Daemen MJ. The a-smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol 1994; 145: 868-875.
17. Tsuruda T, Kato J, Hatakeyama K, Masuyama H, Cao YN, Imamura T, et al. Antifibrotic effect of adrenomedullin on coronary adventitia in angiotensin II-induced hypertensive rats. Car-diovasc Res 2005; 65: 921-929.
18. Ryan ST, Koteliansky VE, Gotwals PJ, Lindner V. Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury. J Vasc Res 2003; 40: 37-46.
19. Shimada K. Immune system and atherosclerotic disease: Heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ J 2009; 73: 994-1001.
20. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005; 23: 344-346.
21. Boyle JJ, Harrington HA, Piper E, Elderfield K, Stark J, Landis RC, et al. Coronary intraplaque hemorrhage evokes a novel athero-protective macrophage phenotype. Am J Pathol 2009; 174: 1097-1108.
22. Tsuruda T, Kato J, Hatakeyama K, Kojima K, Yano M, Yano Y, et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 2008; 102: 1368-1377.
23. Högger P, Dreier J, Droste A, Buck F, Sorg C. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cys-teine-rich family (CD163). J Immunol 1998; 161: 1883-1890.
24. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al. Identification of the haemoglobin scavenger receptor. Nature 2001; 409: 198-201.
25. Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: Potential biological implications. J Immunol 2007; 178: 8183-8194.
26. Schaer CA, Schoedon G, Imhof A, Kurrer MO, Schaer DJ. Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Circ Res 2006; 99: 943-950.
27. Kuwahara F, Kai H, Tokuda K, Niiyama H, Tahara N, Kusaba K, et al. Roles of intercellular adhesion molecule-1 in hypertensive cardiac remodeling. Hypertension 2003; 41: 819-823.
28. Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman RB, Scott NA, et al. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 2001; 104:2228-2235.
29. Gong Y, Hart E, Shchurin A, Hoover-Plow J. Inflammatory mac-rophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest 2008; 118: 3012-3024.
30. Valent P, Sillaber C, Bettelheim P. The growth and differentiation of mast cells. Prog Growth Factor Res 1991; 3: 27-41.
31. Edling CE, Hallberg B. c-Kit: A hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol 2007; 39: 1995-1998.
32. Kirshenbaum AS, Goff JP, Albert JP, Kessler SW, Metcalfe DD. Fibroblasts determine the fate of Fce RI+ cell populations in vitro by selectively supporting the viability of mast cells while internalizing and degrading basophils. Int Arch Allergy Immunol 1994; 105: 374-380.
33. Krishnaswamy G, Ajitawi O, Chi DS. The human mast cell: An overview. Methods Mol Biol 2006; 315: 13-34.
34. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005; 280: 9291-9296.
35. Lohi J, Harvima I, Keski-Oja J. Pericellular substrates of human mast cell tryptase: 72,000 dalton gelatinase and fibronectin. J Cell Biochem 1992; 50: 337-349.
36. Leskinen M, Wang Y, Leszczynski D, Lindstedt KA, Kovanen PT. Mast cell chymase induces apoptosis of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21: 516-522.
37. Hiromatsu Y, Toda S. Mast cells and angiogenesis. Microsc Res Tech 2003; 60: 64-69.
38. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 2007; 13: 719-724.
39. Shiota N, Rysä J, Kovanen PT, Ruskoaho H, Kokkonen JO, Lindstedt KA. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens 2003; 21: 1935-1944.
40. Higuchi H, Hara M, Yamamoto K, Miyamoto T, Kinoshita M, Yamada T, et al. Mast cells play a critical role in the pathogenesis of viral myocarditis. Circulation 2008; 118: 363-372.
41. Hara M, Ono K, Hwang MW, Iwasaki A, Okada M, Nakatani K, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med 2002; 195: 375-381.
42. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79: 215-262.
43. Jugdutt BI. Extracellular matrix and cardiac remodeling. In: Villarreal FJ, editor. Interstitial fibrosis in heart failure. New York: Springer Science, 2005; 23-55.
44. Shah PK. Inflammation, metalloproteinases, and increased prote-olysis: An emerging pathophysiological paradigm in aortic aneu-rysm. Circulation 1997; 96: 2115-2117.
45. López B, González A, Varo N, Laviades C, Querejeta R, Díez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38: 1222-1226.
46. Querejeta R, López B, González A, Sánchez E, Larman M, Martínez Ubago JL, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: Relation to myo-cardial fibrosis. Circulation 2004; 110: 1263-1268.
47. Kunishige M, Kijima Y, Sakai T, Akutagawa O, Matsuo A, Nishibe A, et al. Transient enhancement of oxidant stress and collagen turnover in patients with acute worsening of congestive heart failure. Circ J 2007; 71: 1893-1897.
48. Sluijter JP, de Kleijn DP, Pasterkamp G. Vascular remodeling and protease inhibition-bench to bedside. Cardiovasc Res 2006; 69: 595-603.
49. Ando J, Yamamoto K. Vascular mechanobiology: Endothelial cell responses to fluid shear stress. Circ J 2009; 73: 1983-1992.
50. Sho E, Sho M, Singh TM, Nanjo H, Komatsu M, Xu C, et al. Arterial enlargement in response to high flow requires early expression of matrix metalloproteinases to degrade extracellular matrix. Exp Mol Pathol 2002; 73: 142-153.
51. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-1375.
52. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 2002; 90: 251-262.
53. Matsunaga T, Abe N, Kameda K, Hagii J, Fujita N, Onodera H, et al. Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int J Car-diol 2005; 105: 203-208.
54. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 1995; 270: 5872-5876.
55. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG. Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem 1991; 266: 7870-7875.
56. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110: 625-632.
57. Tomanek RJ. Response of the coronary vasculature to myocardial hypertrophy. J Am Coll Cardiol 1990; 15: 528-533.
58. Ritman EL, Lerman A. The dynamic vasa vasorum. Cardiovasc Res 2007; 75: 649-658.
59. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003; 9: 677-684.
60. Hughes CC. Endothelial-stromal interactions in angiogenesis. Curr Opin Hematol 2008; 15: 204-209.
61. Cai WJ, Koltai S, Kocsis E, Scholz D, Kostin S, Luo X, et al. Remodeling of the adventitia during coronary arteriogenesis. Am J Physiol Heart Circ Physiol 2003; 284: H31-H40.
62. Doyle B, Caplice N. Plaque neovascularization and antiangio-genic therapy for atherosclerosis. J Am Coll Cardiol 2007; 49: 2073-2080.
63. Paik DC, Fu C, Bhattacharya J, Tilson MD. Ongoing angiogene-sis in blood vessels of the abdominal aortic aneurysm. Exp Mol Med 2004; 36: 524-533.
64. Kwon HM, Sangiorgi G, Ritman EL, McKenna C, Holmes DRJ, Schwartz RS, et al. Enhanced coronary vasa vasorum neovascu-larization in experimental hypercholesterolemia. J Clin Invest 1998; 101: 1551-1556.
65. Hao Q, Wang L, Tang H. Vascular endothelial growth factor induces protein kinase D-dependent production of pro-inflammatory cytokines in endothelial cells. Am J Physiol Cell Physiol 2009; 296: C821-C827.
66. Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn G.MD, et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 2008; 51: 1258-1265.
67. Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, Haase VH. Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol 2004; 287: F1223-F1232.
68. Zhao Q, Ishibashi M, Hiasa K, Tan C, Takeshita A, Egashira K. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 2004; 44: 264-270.
69. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascular-ization in human coronary atherosclerosis: Its origin and patho-physiological significance. Hum Pathol 1995; 26: 450-456.
70. de Boer OJ, van der Wal AC, Teeling P, Becker AE. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: A prominent role for neovascularization? Cardiovasc Res 1999; 41: 443-449.
71. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: Implications for plaque vulnerability. Circulation 2004; 110: 2032-2038.
72. Barker SG, Tilling LC, Miller GC, Beesley JE, Fleetwood G, Stavri GT, et al. The adventitia and atherogenesis: Removal initiates intimal proliferation in the rabbit which regresses on generation of a 'neoadventitia'. Atherosclerosis 1994; 105: 131-144.
73. Akiyama-Uchida Y, Ashizawa N, Ohtsuru A, Seto S, Tsukazaki T, Kikuchi H, et al. Norepinephrine enhances fibrosis mediated by TGF-ß in cardiac fibroblasts. Hypertension 2002; 40: 148-154.
74. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26: 809-820.
75. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardio-vasc Res 1993; 27: 2130-2134.
76. Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol 2003; 284: H176-H184.
77. Li P, Wang D, Lucas J, Oparil S, Xing D, Cao X, et al. Atrial natriuretic peptide inhibits transforming growth factor ß-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res 2008; 102: 185-192.
78. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-ß in primary human cardiac fibroblasts: Fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004; 94: 453-461.
79. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002; 91: 1127-1134.
80. Horio T, Tokudome T, Maki T, Yoshihara F, Suga S, Nishikimi T, et al. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology 2003; 144: 2279-2284.
81. Tsuruda T, Kato J, Kitamura K, Kawamoto M, Kuwasako K, Imamura T, et al. An autocrine or a paracrine role of adrenomedul-lin in modulating cardiac fibroblast growth. Cardiovasc Res 1999; 43: 958-967.
82. Tsuruda T, Kato J, Cao YN, Hatakeyama K, Masuyama H, Imamura T, et al. Adrenomedullin induces matrix metalloprotein-ase-2 activity in rat aortic adventitial fibroblasts. Biochem Biophys Res Commun 2004; 325: 80-84.
83. Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am J Cardiol 2001; 87: 25C-32C.
84. Nakahara T, Takata Y, Hirayama Y, Asano K, Adachi H, Shiokawa G, et al. Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide. Circ J 2007; 71: 716-721.
85. Miyazaki M, Takai S, Jin D, Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther 2006; 112: 668-676.
86. de Lannoy LM, Schuijt MP, Saxena PR, Schalekamp MA, Danser AH. Angiotensin converting enzyme is the main contributor to angiotensin I-II conversion in the interstitium of the isolated perfused rat heart. J Hypertens 2001; 19: 959-965.
87. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 1269-1281.
88. Kurosawa Y, Katoh M, Doi H, Narita H. Tissue angiotensin-converting enzyme activity plays an important role in pressure overload-induced cardiac fibrosis in rats. J Cardiovasc Pharmacol 2002; 39: 600-609.
89. Barreto-Chaves ML, Aneas I, Krieger JE. Glucocorticoid regulation of angiotensin-converting enzyme in primary culture of adult cardiac fibroblasts. Am J Physiol Regul Integr Comp Physiol 2001; 280: R25-R32.
90. Saijonmaa O, Nyman T, Kosonen R, Fyhrquist F. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am J Physiol Heart Circ Physiol 2001; 280: H885-H891.
91. Petrov VV, Fagard RH, Lijnen PJ. Transforming growth factor-ß 1 induces angiotensin-converting enzyme synthesis in rat cardiac fibroblasts during their differentiation to myofibroblasts. J Renin Angiotensin Aldosterone Syst 2000; 1: 342-352.
92. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-2767.
93. Hollenberg NK. Implications of species difference for clinical investigation: Studies on the renin-angiotensin system. Hypertension 2000; 35: 150-154.
94. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995; 25: 227-234.
95. Cameron VA, Rademaker MT, Ellmers LJ, Espiner EA, Nicholls MG, Richards AM. Atrial (ANP) and brain natriuretic peptide (BNP) expression after myocardial infarction in sheep: ANP is synthesized by fibroblasts infiltrating the infarct. Endocrinology 2000; 141: 4690-4697.
96. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-560.
97. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998; 393: 333-339.
98. Tsuruda T, Kato J, Hatakeyama K, Yamashita A, Nakamura K, Imamura T, et al. Adrenomedullin in mast cells of abdominal aortic aneurysm. Cardiovasc Res 2006; 70: 158-164.
99. Tsuruda T, Costello-Boerrigter LC, Burnett JC Jr. Matrix metallo-proteinases: Pathways of induction by bioactive molecules. Heart Fail Rev 2004; 9: 53-61.
100. Harada M, Itoh H, Nakagawa O, Ogawa Y, Miyamoto Y, Kuwahara K, et al. Significance of ventricular myocytes and non-myocytes interaction during cardiocyte hypertrophy: Evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac non-myocytes. Circulation 1997; 96: 3737-3744.
101. Chilton L, Giles WR, Smith GL. Evidence of intercellular coupling between co-cultured adult rabbit ventricular myocytes and myofibroblasts. J Physiol 2007; 583: 225-236.
102. Miragoli M, Salvarani N, Rohr S. Myofibroblasts induce ectopic activity in cardiac tissue. Circ Res 2007; 101: 755-758.
103. Sarkar S, Vellaichamy E, Young D, Sen S. Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: Role of myocytes. Am J Physiol Heart Circ Physiol 2004; 287: H107-H117.
104. Moreno PR, Purushothaman KR, Fuster V, O'Connor WN. Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta: Implications for plaque vulnerability. Circulation 2002; 105: 2504-2511.
105. De Leon H, Ollerenshaw JD, Griendling KK, Wilcox JN. Adventitial cells do not contribute to neointimal mass after balloon angioplasty of the rat common carotid artery. Circulation 2001; 104: 1591-1593.
106. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996; 94: 1655-1664.
107. Varo N, Iraburu MJ, Varela M, López B, Etayo JC, Díez J. Chronic AT1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000; 35: 1197-1202.
108. Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-2517.
109. Kawasaki D, Kosugi K, Waki H, Yamamoto K, Tsujino T, Masuyama T. Role of activated renin-angiotensin system in myo-cardial fibrosis and left ventricular diastolic dysfunction in diabetic patients: Reversal by chronic angiotensin II type 1A receptor blockade. Circ J 2007; 71: 524-529.
110. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-ß 1 in cardiac fibroblasts and myofibroblasts. JMol Cell Cardiol 1997; 29: 1947-1958.
111. Yu CM, Tipoe GL, Wing-Hon Lai K, Lau CP. Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1207-1215.
112. Susic D, Varagic J, Ahn J, Matavelli L, Frohlich ED. Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR. Am J Physiol Heart Circ Physiol 2007; 292: H175-H179.
113. Masuyama H, Tsuruda T, Kato J, Imamura T, Asada Y, Stasch JP, et al. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension 2006; 48: 972-978.
114. Dourron HM, Jacobson GM, Park JL, Liu J, Reddy DJ, Scheel ML, et al. Perivascular gene transfer of NADPH oxidase inhibitor suppresses angioplasty-induced neointimal proliferation of rat carotid artery. Am J Physiol Heart Circ Physiol 2005; 288: H946-H953.
115. Bosmans JM, Vrints CJ, Kockx MM, Bult H, Cromheeke KM,Herman AG. Continuous perivascular L-arginine delivery increases total vessel area and reduces neointimal thickening after experimental balloon dilatation. Arterioscler Thromb Vasc Biol 1999;19: 767-776.
116. Wilson SH, Herrmann J, Lerman LO, Holmes DRJ, Napoli C, Ritman EL, et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002; 105: 415-418.
117. Kohno T, Anzai T, Naito K, Sugano Y, Maekawa Y, Takahashi T, et al. Angiotensin-receptor blockade reduces border zone myocar-dial monocyte chemoattractant protein-1 expression and macro-phage infiltration in post-infarction ventricular remodeling. Circ J 2008; 72: 1685-1692.
118. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, et al. PPAR activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007; 6: 137-143.
119. Hoshijima M, Chien KR. Mixed signals in heart failure: Cancer rules. J Clin Invest 2002; 109: 849-855.
120. Aharinejad S, Sioud M, Lucas T, Abraham D. Targeting stromal-cancer cell interactions with siRNAs. Methods Mol Biol 2009; 487: 243-266.
121. Clemente CF, Tornatore TF, Theizen TH, Deckmann AC, Pereira TC, Lopes-Cendes I, et al. Targeting focal adhesion kinase with small interfering RNA prevents and reverses load-induced cardiac hypertrophy in mice. Circ Res 2007; 101: 1339-1348.